Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Summary
Artiva Biotherapeutics will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. The company positions AlloNK as an off-the-shelf NK cell therapy for autoimmune diseases and says it is advancing the program across several indications. Artiva also plans to start a Phase 3 registrational trial in refractory rheumatoid arthritis in 2026. The announcement mainly serves as an investor and visibility update rather than a major commercial product release.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected